SSA
FATE icon

Schonfeld Strategic Advisors’s Fate Therapeutics FATE Stock Holding History

Schonfeld Strategic Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$179K Buy
+66,158
New +$122K ﹤0.01% 2214
2026
Q1 		– Sell
-192,682
Closed -$189K – 2362
2025
Q4 		$189K Sell
192,682
-351,905
-65% -$423K ﹤0.01% 1727
2025
Q3 		$686K Sell
544,587
-386,222
-41% -$416K ﹤0.01% 1546
2025
Q2 		$1.04M Sell
930,809
-6,863,704
-88% -$7.98M 0.01% 1287
2025
Q1 		$6.16M Buy
+7,794,513
New +$9.55M 0.04% 467
2024
Q2 		– Sell
-886,925
Closed -$6.51M – 2280
2024
Q1 		$6.51M Buy
886,925
+389,468
+78% +$2.41M 0.04% 543
2023
Q4 		$1.86M Buy
497,457
+478,257
+2,491% +$1.13M 0.01% 822
2023
Q3 		$40.7K Buy
+19,200
New +$63.6K ﹤0.01% 1544
2023
Q1 		– Sell
-139,000
Closed -$1.4M – 2250
2022
Q4 		$1.4M Buy
139,000
+54,144
+64% +$1.02M 0.01% 984
2022
Q3 		$1.9M Sell
84,856
-15,736
-16% -$455K 0.02% 888
2022
Q2 		$2.49M Buy
+100,592
New +$2.78M 0.02% 684
2021
Q1 		– Sell
-4,117
Closed -$375K – 1893
2020
Q4 		$375K Sell
4,117
-4,996
-55% -$310K 0.01% 1129
2020
Q3 		$364K Buy
+9,113
New +$318K 0.01% 1020
2019
Q4 		– Sell
-96,400
Closed -$1.5M – 1352
2019
Q3 		$1.5M Buy
96,400
+85,035
+748% +$1.63M 0.04% 378
2019
Q2 		$231K Buy
+11,365
New +$205K 0.01% 848
2018
Q4 		– Sell
-116,100
Closed -$1.89M – 1121
2018
Q3 		$1.89M Buy
+116,100
New +$1.37M 0.08% 293

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Schonfeld Strategic Advisors's FATE Position: Q2 2026 in Review

Schonfeld Strategic Advisors opened a new position in Fate Therapeutics (FATE) in Q2 2026: 66,158 shares worth $179K. The stake represents ﹤0.01% of the portfolio and ranks #2214 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in FATE as recently as Q4 2025.

Schonfeld Strategic Advisors first reported a position in FATE in Q3 2018 and has held it in 16 quarters since. The position peaked at $6.51M in Q1 2024. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Schonfeld Strategic Advisors held 66,158 shares of Fate Therapeutics worth $179K as of Q2 2026.
  • Fate Therapeutics was a new Schonfeld Strategic Advisors position in Q2 2026.
  • Fate Therapeutics made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #2214 holding.
  • Schonfeld Strategic Advisors first reported a position in Fate Therapeutics in Q3 2018 and has held it in 16 quarters since.
  • Schonfeld Strategic Advisors's Fate Therapeutics position peaked at $6.51M in Q1 2024.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.